Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
about
PD-L1 expression in human cancers and its association with clinical outcomesA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsB cell regulation of the anti-tumor response and role in carcinogenesisRole of the tumor microenvironment in mature B-cell lymphoid malignanciesThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialNovel immunotherapies in lymphoid malignanciesPromises and paradoxes of regulatory T cells in inflammatory bowel diseaseRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsImmunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigationsNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyRecent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomasImmune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerImmune Modulation in Hematologic MalignanciesThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsImmune Checkpoint Blockade in Cancer TherapyImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?New antibody approaches to lymphoma therapyCheckpoint modulation--A new way to direct the immune system against renal cell carcinomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDifferential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.The PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationPD-1 and its ligands are important immune checkpoints in cancerTargeting immune checkpoints in malignant gliomaPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lymphoma: immune evasion strategiesA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaMechanisms of action of therapeutic antibodies for cancerPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaImmunotherapy in hematologic malignancies: past, present, and future.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a reviewEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Immune checkpoint inhibitors in clinical trialsEarly failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.
P2860
Q26738361-20399EC7-07D5-4569-9EA6-621F7A7C1A7EQ26738729-BD5C2DFB-4A69-4D53-9669-B81FDC445F68Q26738867-00FF38A3-589A-42AE-A7C2-325414BC1B2AQ26748775-6C2E7742-3E6A-423C-B001-4FE473A26223Q26766066-A1DAB3A4-FBA5-4566-AFC6-BF2FA4877221Q26769884-386CC17E-49CF-4245-8B13-76D1F5F5E078Q26777394-00F25AC7-BACC-4E39-845F-B11168CD6570Q26777557-D516E766-92F8-4CB4-BB4D-E80E0F093F26Q26779221-2C5F2C8E-4A57-4EC1-8C4D-979F2CD56278Q26781038-C4008FB7-C957-4EFE-9B59-25D51F618E94Q26782270-3CC9751F-B107-461E-938C-37ACAE48CC2FQ26784108-40DEB683-D07F-4DB3-8F46-6F656240D91FQ26795509-9BE00CFC-5646-407E-8674-4552A8DA4201Q26796307-FD0D070C-7EC1-4FE1-AB04-0DB3D5BFCFB2Q26797478-35E86009-B8DB-4986-A256-F4F642FE81D9Q26830509-63757320-6039-4F30-8877-78A5D0388858Q27003955-AC53E8F4-847F-4FF0-9DA5-54C72CDE54DEQ27022373-5F7226CE-F294-42E6-A2C7-CD9C1EBD1B31Q27025873-436230C3-ADFA-4AAA-9355-C299BBF4DF3FQ27304386-B09958FF-9CE4-478D-9100-B1F677B1E2F5Q27853176-E05BBD71-4568-4C12-AFFD-07B8EF3864E1Q28066941-5B987D43-6348-4F08-A4BC-B30292F95BE5Q28069485-CA0BB9C0-0D24-421D-AD48-B50B5CEF3069Q28072012-BF1748A0-D473-432B-A99E-7D2BCCAA80BDQ28075712-E4046F34-0DB3-4DC8-9B52-C63A64959284Q28076071-F01AD049-016E-40CC-B710-10AF10858601Q28080705-D563B14D-6D72-4680-85A7-4B78302F2726Q28087576-BEE511CF-CFAC-46DD-B619-550E221DBBFBQ28088496-D2D84569-A1A7-408D-A237-440C5C8DF0E5Q28385366-011235A7-156A-446F-9728-A28F273A75BEQ29620878-25107EEB-0F55-4473-B5F2-60C89E941539Q33593865-925E7637-EDD9-4767-A4F9-C74A97F00186Q33622342-CDCAA273-9692-43EF-8AB7-455D16879DA2Q33632104-1339EE72-2EA0-444E-BE47-C41BD4621C3FQ33638083-8C386D77-C6F5-44E3-AB13-A9F4D3AD109CQ33645590-8114416C-4B80-431D-9349-BFB409202BE2Q33704061-65DB3D09-8598-40AF-BF08-9A400CFE6278Q34309394-A723C3DD-7983-4C41-98C5-FF9974C6195BQ34325329-F88C23EA-0895-465D-A9D2-81B926FE5BA0Q34380489-A23CB901-2012-4556-BB66-E59C0167F084
P2860
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Disabling immune tolerance by ...... international phase II trial.
@en
type
label
Disabling immune tolerance by ...... international phase II trial.
@en
prefLabel
Disabling immune tolerance by ...... international phase II trial.
@en
P2093
P2860
P50
P356
P1476
Disabling immune tolerance by ...... international phase II trial.
@en
P2093
Arnon Nagler
David A Rizzieri
David Andorsky
David E Avigan
Edie A Weller
Edmund K Waller
Edward D Ball
H Kent Holland
James R Mason
John M Timmerman
P2860
P304
P356
10.1200/JCO.2012.48.3685
P407
P577
2013-10-14T00:00:00Z